Medication Classification: Stiolto, Anoro Ellipta, and Fluticasone Propionate
No, Stiolto (tiotropium bromide/olodaterol) and Anoro Ellipta (umeclidinium/vilanterol) are NOT glucocorticoids—they are long-acting bronchodilator combinations (LAMA/LABA), while fluticasone propionate IS a glucocorticoid (inhaled corticosteroid). 1, 2, 3
Stiolto Respimat (Tiotropium/Olodaterol)
Stiolto is a fixed-dose combination of two bronchodilators: tiotropium bromide (a long-acting muscarinic antagonist/LAMA) and olodaterol (a long-acting β2-adrenergic agonist/LABA). 1
This medication contains no corticosteroid component whatsoever—it provides dual bronchodilation through two different mechanisms of action without any anti-inflammatory glucocorticoid activity. 1, 4
Tiotropium/olodaterol is indicated for long-term maintenance treatment of COPD and is administered once daily via the Respimat inhaler device. 1, 5
Anoro Ellipta (Umeclidinium/Vilanterol)
Anoro Ellipta is also a LAMA/LABA combination bronchodilator: umeclidinium (long-acting muscarinic antagonist) combined with vilanterol (long-acting β2-agonist). 2, 6
Like Stiolto, Anoro contains no glucocorticoid—it provides bronchodilation only, without inhaled corticosteroid anti-inflammatory effects. 2
Anoro is administered once daily at a dose of umeclidinium 62.5 µg/vilanterol 25 µg and represents an alternative dual bronchodilator option for COPD maintenance therapy. 2, 6
Fluticasone Propionate
Fluticasone propionate is definitively a glucocorticoid—specifically, it is a potent inhaled corticosteroid (ICS) with strong anti-inflammatory properties. 7, 8, 3
Fluticasone propionate is a trifluorinated glucocorticoid with high glucocorticoid receptor affinity (KD of 0.5 nmol/L), making it 1.5-fold more potent than beclomethasone-17-monopropionate and 3-fold more potent than budesonide at the receptor level. 3
This medication has high selectivity for the glucocorticoid receptor with little or no activity at other steroid receptors, and it demonstrates potent anti-inflammatory activity by inhibiting T-cell migration, suppressing cytokine release, and reducing eosinophilic airway inflammation. 3
Fluticasone propionate is used in both asthma and COPD management, often in combination with long-acting bronchodilators (such as fluticasone/salmeterol combinations). 7, 9
Clinical Implications of This Distinction
LAMA/LABA combinations (Stiolto, Anoro) do not carry the pneumonia risk associated with inhaled corticosteroid-containing regimens, which have a number needed to harm of 33 patients treated for one year. 10
Patients on dual bronchodilator therapy (LAMA/LABA) who continue to experience frequent exacerbations (≥2 moderate exacerbations or ≥1 severe exacerbation requiring hospitalization per year) should be escalated to triple therapy by adding an inhaled corticosteroid like fluticasone propionate. 2, 6
Never combine two different inhaled corticosteroids (such as adding fluticasone propionate to a regimen already containing another ICS)—this represents irrational polypharmacy and unnecessarily increases systemic corticosteroid exposure and adverse effects. 10